WHO designates “Lambda” as global variant of interest

By on .

By Daniel R. Lucey MD, MPH, FIDSA In its weekly COVID-19 epidemiology update this week the World Health Organization stated that the “Lambda” was designated a variant of interest “based upon evidence of continued emergence and suspected phenotypic implications” (boldtype below was added). “Authorities in Peru reported that 81% of COVID-19 cases sequenced since April 2021 […]

UN 5th High Level Meeting on HIV/AIDS: Civil society says “Yes — AND” to the 2021 political declaration

By on .

The following is a guest post by Maureen Luba Milambe, African Regional Advocacy Advisor, AVAC On Tuesday (June 8), the UN General Assembly voted overwhelmingly to approve the 2021 Political Declaration on HIV and AIDS introduced as part of the now fifth High Level Meeting on HIV/AIDS. Previous Declarations were accepted by unanimous consent, following […]

HHS cites increasing rate of variants P.1 and B.351 in recommending use of Regeneron (but no longer Lilly) monoclonal antibody combination in eight states

By on .

By Daniel R. Lucey MD, MPH, FIDSA On Wednesday (May 26) the Department of Health and Human Services made the clinically-relevant important update below.  (I anticipate more than these eight states to be included in the weeks and months ahead as the variants P.1. and B.1. 351 continue to spread in the United States). ​“Important […]

As substance use disorders rise in the midst of a pandemic, a new law is needed now to facilitate treatment

By on .

While America’s epidemic of opioid use was already a burgeoning health crisis, it has worsened markedly since the onset of the COVID-19 pandemic. Between September 2019 and September 2020, the U.S. Centers for Disease Control and Prevention estimates, deaths caused by opioid overdoses have increased by nearly a third. Dr. Ellen Eaton, of the Outpatient-Based […]

Will the China report on 266 patients Nov. 17-Dec. 31, 2019 be made public by China, WHO, or by WHA resolution next week?

By on .

By Daniel R. Lucey MD, MPH, FIDSA In a recent Science paper by Pekar, Worobey and colleagues titled “Timing the SARS-CoV-2 index case in Hubei province” the authors conclude “Our results define the period between mid-October and mid-November 2019 as the plausible interval when the first case of SARS-CoV-2 emerged in Hubei province.” Referencing reporting […]

Take the Science Speaks readership survey

By on .

Science Speaks, the global infectious disease blog produced by the Infectious Diseases Society of American and its HIV Medicine Association, is seeking input from its readers on how we can best keep you posted on breaking news and analysis of infectious diseases developments around the world. Your answers to a brief survey will help us […]

Variant B.1.617 spreads in India and UK, and arrives in US: get vaccinated ASAP

By on .

By Daniel R. Lucey MD, MPH, FIDSA The World Health Organization declared the SARS-CoV-2 variant “B.1.617”, first recognized in India, a “variant of concern” May 10. The United Kingdom did the same May 7 for the sublineage “B.1.617.2.” The United States has found and reported only a small number of cases, in at least five […]

Changing the narrative: Caring for Asian American and Pacific Islander patients with HIV

By on .

Wednesday, May 19 is National Asian & Pacific Islander HIV/AIDS Awareness Day. Founded by the Banyan Tree Project, the day serves to raise awareness of the impacts of HIV stigma on Asian and Pacific Islander people. Here, Los Angeles-based physician Dr. Jen Chang discusses the importance of work that provides the support of a community […]

Talk to us!

By on .

Science Speaks, the global infectious disease blog produced by the Infectious Diseases Society of American and its HIV Medicine Association, is seeking input from its readers on how we can best keep you posted on breaking news and analysis of infectious diseases developments around the world. Your answers to a brief survey will help us […]